Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 38, n° 6
pages 938-944 (juin 1998)
Doi : 10.1016/S0190-9622(98)70590-0
accepted : 4 Mars 1998
Administration of DAB389 IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial

Jerry Bagel, MDa, W.Thomas Garland, MDb, Debra Breneman, MDc, Michael Holick, MDd, T.W. Littlejohn, MDe, David Crosby, MDf, Holly Faust, MDg, David Fivenson, MDh, Jean Nichols, PhDi
East Windsor and Lawrenceville, New Jersey; Cincinnati, Ohio; Boston and Hopkinton, Massachusetts; Winston-Salem, North Carolina; Milwaukee, Wisconsin; Indianapolis, Indiana; and Detroit, Michigan 
From the Psoriasis Treatment Center of Central New Jersey, East Windsor a; Lawrence Clinical Research, Lawrenceville b; University Dermatology Consultants, Cincinnati c; Department of Dermatology, Boston University Medical Centerd; Department of Dermatology, Piedmont Research Associates, Winston-Salem e; Department of Dermatology, Medical College of Wisconsin, Milwaukee f; Department of Dermatology, Indiana University School of Medicine, Indianapolis g; Department of Dermatology, Henry Ford Hospital, Detroit h; and Seragen, Inc., Hopkinton. i 


Background: Current therapies for recalcitrant psoriasis focus on immunoregulation and targeting of activated T-lymphocytes rather than keratinocytes. Previous studies with low doses of the lymphocyte-selective fusion protein DAB389 IL-2 have shown benefit to patients with psoriasis. Objective: We examined the safety and efficacy of DAB389 IL-2 in 41 volunteers receiving more frequent and higher doses than in a previous trial. Methods: Patients were randomized to receive either placebo or 5, 10, or 15 mg/kg daily of DAB389 IL-2 intravenously for 3 consecutive days each week for 4 consecutive weeks with a subsequent 4-week observation period. Results: Of the placebo group, 17% (2 of 12) exhibited at least 50% improvement from baseline Psoriasis Area and Severity Index scores at the end of the study, whereas 24% of all treated patients (7 of 29) showed the same improvement. Overall, 3 of 12 (25%) patients given placebo as opposed to 12 of 29 (41%) patients treated with DAB389 IL-2 improved to this same extent at some point during the study. The rate of improvement for treated patients was significantly greater than for placebo patients (p = 0.04; repeated measures ANOVA). Among treated patients, decreases in Psoriasis Area and Severity Index scores were paralleled by changes in the Physician’s Global Assessment and the Dermatology Life Quality Index. Treatment in ten patients was discontinued because of adverse events. Flu-like symptoms were the most common with severity increasing at the two higher doses. Only one serious adverse event was reported. This occurred in a patient receiving 5 mg/kg daily who experienced vasospasm and a coagulopathy resulting in arterial thrombosis. Conclusion: Our findings are consistent with the potential antipsoriatic activity of DAB389 IL-2 demonstrated in an earlier study. However, DAB389 IL-2 was less well tolerated at this dosing regimen, particularly at the highest dose, and it was too toxic at these doses and schedules to be considered in the routine treatment of psoriasis. (J Am Acad Dermatol 1998;38:938-44.)

The full text of this article is available in PDF format.

 Supported by a grant from Seragen, Inc.
 Reprint requests: Jerry Bagel, MD, Psoriasis Treatment Center of Central New Jersey, East Windsor Professional Park, Suite G, East Windsor, NJ 08520.
 0190-9622/98/$5.00 + 0   16/1/90033

© 1998  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@